Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife
Extensive worldwide reservoirs of rabies virus (RV) in wildlife and stray dogs continue to pose a serious risk of lethal infection of humans and cause a high economic burden. Immunization of wildlife and stray dogs with live vaccines is the only effective method to control and eventually eliminate rabies in carnivore species worldwide. In this application we propose to select canine adenovirus type-2 (CAV2) clones that optimally express the rabies virus (RV) G protein from previously engineered replication-competent CAV 2 - RVG constructs. These selected CAV 2-RVG viruses will be evaluated for safety and efficacy in laboratory animals as an initial proof of concept.
Small Business Information at Submission:
Jeffrey A. Mattis
Sr. Vice President, Scientific Affairs
Molecular Targeting Technologies, Inc.
882 S. Matlack Street Suite 105 West Chester, PA 19382
Number of Employees: